



ALK  
Investor Relations Department  
BÅ,ge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### OMX: ALKB

Last Trade:	719.00
Trade Time:	4:59 PM ET Feb 22, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	646.00 - 1133.00
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Feb 21, 2018*  
[New medicine for house dust mite allergic rhinitis and allergic asthma now available in France](#)

*Feb 16, 2018*  
[ALK's partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan](#)

*Feb 13, 2018*  
[Annual General Meeting in ALK-Abelló A/S on 12 March 2018](#)

*Feb 6, 2018*  
[ALK releases its annual report 2017](#)

*Jan 30, 2018*  
[Release date of annual report 2017 and audio cast](#)

## Upcoming Events [\[ View all \]](#)

*Mar 12, 2018*  
[AGM](#)

*Mar 15, 2018*  
[Carnegie Healthcare Seminar, Stockholm](#)